JBIO - Latest News
Jade Biosciences, Inc. (JBIO), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $816.7M. Beta to the broader market is 1.45.
The article list below shows the most recent JBIO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent JBIO Headlines
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
seekingalpha.com - Sep 30, 2026
Jade Biosciences, Inc.
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
globenewswire.com - Sep 30, 2026
JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing JADE3
Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to Brokerages
defenseworld.net - Sep 28, 2026
Jade Biosciences, Inc. (NASDAQ: JBIO - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten research firms that ar
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
seekingalpha.com - Sep 9, 2026
Jade Biosciences, Inc.
Jade Biosciences to Participate in Upcoming Conferences
globenewswire.com - Sep 1, 2026
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc.
How News Affects JBIO Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track JBIO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked JBIO news questions
- What is the latest JBIO news headline?
- The most recent JBIO headline (Sep 30, 2026) is "Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the JBIO news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What JBIO news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual JBIO options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.